Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16044
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGupta, VB-
dc.contributor.authorDoecke, JD-
dc.contributor.authorHone, E-
dc.contributor.authorPedrini, S-
dc.contributor.authorLaws, Simon M-
dc.contributor.authorThambisetty, M-
dc.contributor.authorBush, AI-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorAmes, David-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorMacaulay, S Lance-
dc.contributor.authorRembach, A-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorAIBL Research Group-
dc.date.accessioned2016-06-17T04:00:32Z-
dc.date.available2016-06-17T04:00:32Z-
dc.date.issued2015-12-22-
dc.identifier.citationAlzheimer's & Dementia (Amst) 2016; 3: 18-26en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16044-
dc.description.abstractINTRODUCTION: For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD. METHODS: Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele status, mini-mental state examination score, plasma amyloid beta (Aβ), neocortical Aβ burden (as measured by Pittsburgh compound B-positron emission tomography), and total adjusted hippocampus volume. RESULTS: ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as compared with healthy controls (HC; P < .0001). ApoJ significantly correlated with both "standardized uptake value ratio" (SUVR) and hippocampus volume and weakly correlated with the plasma Aβ1-42/Aβ1-40 ratio. Plasma apoJ predicted both MCI and AD from HC with greater than 80% accuracy for AD and greater than 75% accuracy for MCI at both baseline and 18-month time points. DISCUSSION: Mean apoJ levels were significantly higher in both MCI and AD groups. ApoJ was able to differentiate between HC with high SUVR and HC with low SUVR via APOE ε4 allele status, indicating that it may be included in a biomarker panel to identify AD before the onset of clinical symptoms.en
dc.subjectApolipoprotein Jen
dc.subjectBiomarkersen
dc.subjectBrain amyloid betaen
dc.subjectHippocampus volumeen
dc.subjectPlasmaen
dc.titlePlasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of agingen
dc.typeJournal Articleen
dc.identifier.journaltitleAlzheimer's & Dementia (Amsterdam,Netherlands)en
dc.identifier.affiliationAcademic Unit for Psychiatry of Old age, St. George's Hospital, The University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationCSIRO Food and Nutrition Flagship, Parkville, Australiaen
dc.identifier.affiliationSchool of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australiaen
dc.identifier.affiliationOxidation Biology Unit, The Florey Institute, The University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationSchool of Medical Sciences, Edith Cowan University, Joondalup, WA, Australiaen
dc.identifier.affiliationCooperative Research Centre for Mental Health, Melbourne, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Australiaen
dc.identifier.affiliationUnit of Clinical and Translational Neuroscience Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USAen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australiaen
dc.identifier.affiliationCSIRO Health and Biosecurity, Brisbane, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27239546en
dc.identifier.doi10.1016/j.dadm.2015.12.001en
dc.type.contentTexten
dc.type.austinJournal Articleen_US
local.name.researcherMasters, Colin L
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Oct 31, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.